Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 26:8:707895.
doi: 10.3389/fmed.2021.707895. eCollection 2021.

The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma

Affiliations

The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma

Tengfei Ma et al. Front Med (Lausanne). .

Abstract

Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at the time of convalescent plasma treatment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients.

Keywords: COVID-19; SARS-CoV-2; antibodies; antibody therapy; convalescent plasma therapy.

PubMed Disclaimer

Conflict of interest statement

This study received funding from Millennium Pharmaceuticals, Octapharma USA, Inc. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer VB declared a shared affiliation, with the authors CW, AC, WG, JS, SK, SB, RW, and MJ to the handling editor at the time of the review.

Figures

Figure 1
Figure 1
Trajectories of daily status improvement/worsening. Subgroup analyses include (A) all patients, (B) by age, (C) by sex, (D) by initial clinical status, (E) by ICU status prior to transfusion, and (F) by ventilator status prior to transfusion. Net patient scores of 0 = no net change, +1 = net improvement but still hospitalized, −1 = net worsened and still hospitalized, +2 = discharged from hospital, and −2 = patient expiration. Points are the mean score for each day, and gray bands indicate the 95% confidence interval for each data set.

Update of

Similar articles

Cited by

  • Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.
    Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE, Paneth NS, Sullivan DJ, Morkeberg OH, Wright RS, Fairweather D, Bruno KA, Shoham S, Bloch EM, Focosi D, Henderson JP, Juskewitch JE, Pirofski LA, Grossman BJ, Tobian AAR, Franchini M, Ganesh R, Hurt RT, Kay NE, Parikh SA, Baker SE, Buchholtz ZA, Buras MR, Clayburn AJ, Dennis JJ, Diaz Soto JC, Herasevich V, Klompas AM, Kunze KL, Larson KF, Mills JR, Regimbal RJ, Ripoll JG, Sexton MA, Shepherd JRA, Stubbs JR, Theel ES, van Buskirk CM, van Helmond N, Vogt MNP, Whelan ER, Wiggins CC, Winters JL, Casadevall A, Joyner MJ. Senefeld JW, et al. Mayo Clin Proc Innov Qual Outcomes. 2023 Oct 10;7(5):499-513. doi: 10.1016/j.mayocpiqo.2023.09.001. eCollection 2023 Oct. Mayo Clin Proc Innov Qual Outcomes. 2023. PMID: 37859995 Free PMC article.
  • Tackling COVID-19 with neutralizing monoclonal antibodies.
    Corti D, Purcell LA, Snell G, Veesler D. Corti D, et al. Cell. 2021 Jun 10;184(12):3086-3108. doi: 10.1016/j.cell.2021.05.005. Epub 2021 May 26. Cell. 2021. PMID: 34087172 Free PMC article. Review.
  • Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients - propensity-score matched case-control study.
    Tworek A, Jaroń K, Uszyńska-Kałuża B, Rydzewski A, Gil R, Deptała A, Franek E, Wójtowicz R, Życińska K, Walecka I, Cicha M, Wierzba W, Zaczyński A, Król ZJ, Rydzewska G. Tworek A, et al. Int J Infect Dis. 2021 Apr;105:209-215. doi: 10.1016/j.ijid.2021.02.054. Epub 2021 Feb 16. Int J Infect Dis. 2021. PMID: 33607305 Free PMC article.
  • Exercise and Experiments of Nature.
    Joyner MJ, Wiggins CC, Baker SE, Klassen SA, Senefeld JW. Joyner MJ, et al. Compr Physiol. 2023 Jun 26;13(3):4879-4907. doi: 10.1002/cphy.c220027. Compr Physiol. 2023. PMID: 37358508 Free PMC article.

References

    1. U.S. Department of Health & Human Services . CDC COVID Data Tracker. (2020). Available online at: https://covid.cdc.gov/covid-data-tracker/#trends_dailycases (accessed March 31, 2021).
    1. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. (2006) 145:599–609. 10.7326/0003-4819-145-8-200610170-00139 - DOI - PubMed
    1. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al. . The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. (2014) 211:80–90. 10.1093/infdis/jiu396 - DOI - PMC - PubMed
    1. Van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. . Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. (2016) 374:33–42. 10.1056/NEJMoa1511812 - DOI - PMC - PubMed
    1. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. . The effect of convalescent plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis. Mayo Clin Proc. (2021) 96:1262–75. 10.1016/j.mayocp.2021.02.008 - DOI - PMC - PubMed